Home > PJ (current issue) > News / News Centre | Search

PJ Online homeThe Pharmaceutical Journal
Vol 276 No 7395 p410
8 April 2006

This article
Reprint   Photocopy

  Acrobat Reader


News summary


Hypoglycaemia management in some hospitals is inadequate

Insulin

Insulin considered appropriate therapy for hypoglycaemia by some nurses

Treatment of hypoglycaemia in hospital is inadequate and haphazard, according to several research groups presenting their work at the Diabetes UK annual professional conference held in Birmingham last week.

Pharmacists at Guy’s and St Thomas’ NHS Foundation Trust, London, found that routine stock for treating hypoglycaemia was inadequate. In 33 adult wards evaluated, Lucozade was located on one ward and glucose tablets on none. They also found that nurses’ knowledge about hypoglycaemia was lacking. In 27 questionnaire-based interviews, four nurses considered insulin to be an appropriate treatment for hypoglycaemia and two recommended oral products for patients who could not swallow.

The pharmacists found that of 54 patients with blood glucose readings less than 4mmol/L, 15 received sub-optimal treatment (inadequate intake of carbohydrate) and 38 received inappropriate treatment (no treatment or no carbohydrate). Self-contained treatment packs will now be issued to all wards and outpatient clinics and a treatment algorithm will be displayed on wards, say the researchers.

Researchers from the John Radcliffe Hospital, Oxford, say that the management of hypoglycaemia in hospital is often haphazard, with resources disorganised and difficult to access. They have developed a portable kit for wards, which contains all necessary first-line treatment and a trust guideline as an algorithm. Evaluation of the kit has prompted risk reducing and cost-effective changes, they say.

Researchers from the Royal Gwent Hospital, Newport, conducted an audit of 46 junior doctors, which highlighted gaps in the doctors’ knowledge. For example, about 72 per cent did not know what capillary blood value indicated hypoglycaemia and 25 per cent did not name intramuscular glucagon as a treatment option for hypoglycaemia. The researchers conclude that the questionnaire-styled audit raised awareness of trust guidelines and is a useful educational tool.

Back to Top


©The Pharmaceutical Journal